Nk92 Cells | List of Frontiers open access articles

Original Research

Published on 19 Dec 2019

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells

in Cancer Immunity and Immunotherapy

Hong Luo
Xiuqi Wu
Ruixin Sun
Jingwen Su
Yi Wang
Yiwei Dong
Bizhi Shi
Yansha Sun
Hua Jiang
Zonghai Li

Frontiers in Oncology

doi 10.3389/fonc.2019.01448

20,625 views
46 citations

Original Research

Published on 16 May 2022

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

in B Cell Biology

Julia Hambach
William Fumey
Tobias Stähler
Anna Josephine Gebhardt
Gerhard Adam
Katja Weisel
Friedrich Koch-Nolte
Peter Bannas

Frontiers in Immunology

doi 10.3389/fimmu.2022.838406

9,414 views
21 citations

Original Research

Published on 12 Sep 2022

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells

in Cancer Immunity and Immunotherapy

Jia Feng
Haichan Xu
Andrew Cinquina
Zehua Wu
Wenli Zhang
Lihua Sun
Qi Chen
Lei Tian
Le Song
Kevin G. Pinz

Frontiers in Immunology

doi 10.3389/fimmu.2022.997482

9,428 views
21 citations

Original Research

Published on 11 Nov 2025

Engineered NK92 cell-derived exosomes inhibit ovarian cancer progression by degrading GPRC5A

in Cancer Immunity and Immunotherapy

Chaohua Si
Yihan Wang
Yuanyuan Li
Yuqi Chen
Yuxuan Fan
Yunwen Wang
Yanan Tian
Jianen Gao
Xu Ma

Frontiers in Immunology

doi 10.3389/fimmu.2025.1613178

2,239 views
2 citations

Original Research

Published on 13 Jan 2023

A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets

in Cancer Immunity and Immunotherapy

Hee Young Kang
Soo Yun Lee
Hyun Min Kim
Su Ui Lee
Hyunseung Lee
Mi Young Cho
Se-Chan Oh
Seok-Min Kim
Hye Sun Park
Eun Hee Han

Frontiers in Immunology

doi 10.3389/fimmu.2022.1089369

6,167 views
6 citations

Original Research

Published on 18 Apr 2024

Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression

in Cancer Immunity and Immunotherapy

Nayoung Kim
Eunbi Yi
Eunbi Lee
Hyo Jin Park
Hun Sik Kim

Frontiers in Immunology

doi 10.3389/fimmu.2024.1388018

9,701 views
13 citations

Brief Research Report

Published on 08 Jan 2024

Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model

in Cancer Immunity and Immunotherapy

Jusuf Imeri
Paul Marcoux
Matthias Huyghe
Christophe Desterke
Daianne Maciely Carvalho Fantacini
Frank Griscelli
Dimas T. Covas
Lucas Eduardo Botelho de Souza
Annelise Bennaceur Griscelli
Ali G. Turhan

Frontiers in Immunology

doi 10.3389/fimmu.2023.1309010

5,436 views
7 citations

Articles

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells

Engineered NK92 cell-derived exosomes inhibit ovarian cancer progression by degrading GPRC5A

A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets

Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression

Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model